Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers. - Phung CD; Tran TTT; Yeo BZJ; Prajogo RC; Saudjana E; Yeo EYM; Gao C; Nguyen PHD; Jayasinghe MK; Dang XTT; Lixuan CP; Nguyen TM; et al. (Theranostics, 2025)